Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma and an FGFR2 fusion or other rearrangement identified by an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
Created a targeted option for patients with specific FGFR2 alterations after prior treatment.
What research teams should watch
Arrange fusion-capable testing and build phosphate and eye monitoring into follow-up.
PRIMARY RECORDS